Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system

References

• Epstein MS, Ehrenpreis ED, Kulkarni PM. FDA-related matters committee of the American College of Gastroenterology. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol 2014;109:1856–9.
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40–51.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014;13:655–72.
   PubMed Web of Science ®Google Scholar
• Aggarwal RS. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014;32:32–9.
   PubMed Web of Science ®Google Scholar
• Aggarwal RS. What's fueling the biotech engine-2011 to 2012. Nat Biotechnol 2012;30:1191–7.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413–15.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.
   PubMed Web of Science ®Google Scholar
• Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008;20:450–9.
   PubMed Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008;20:460–70.
   PubMed Web of Science ®Google Scholar
• Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol 2014;32:992–1000.
   PubMed Web of Science ®Google Scholar
• Cignetto S, Modica C, Chiriaco C, et al. Dual constant domain-fab: a novel strategy to improve half-life and potency of a met therapeutic antibody. Mol Oncol 2016;10:938–48.
   PubMed Web of Science ®Google Scholar
• Matucci A, Nencini F, Pratesi S, et al. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol 2016;16:576–81.
   PubMed Web of Science ®Google Scholar
• Baker M, Reynolds HM, Lumicisi B, et al. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1:314–22.
   PubMedGoogle Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–27.
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010;146:127–32.
   PubMed Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs 2016;8:536–50.
   PubMed Web of Science ®Google Scholar
• Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 2015;165:270–82.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278–87.
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192–8.
   PubMed Web of Science ®Google Scholar
• Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75–84.
   PubMed Web of Science ®Google Scholar
• Cook-Bruns N. Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer. Oncology 2001;61:58–66.
   PubMed Web of Science ®Google Scholar
• Joslin E, Gray H, Root HF. Insulin in hospital and home. J Metab Res 1992;2:651–99.
   Google Scholar
• Choonara BF, Choonara YE, Kumar P, et al. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 2014;32:1269–82.
   PubMed Web of Science ®Google Scholar
• Hwang SR, Byun Y. Advances in oral macromolecular drug delivery. Expert Opin Drug Deliv 2014;11:1955–67.
   PubMed Web of Science ®Google Scholar
• Tamizi E, Jouyban A. Forced degradation studies of biopharmaceuticals: selection of stress conditions. Eur J Pharm Biopharm 2016;98:26–46.
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005;4:298–306.
   PubMed Web of Science ®Google Scholar
• Razinkov VI, Treuheit MJ, Becker GW. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools. J Biomol Screen 2015;20:468–83.
   PubMedGoogle Scholar
• Uchiyama S. Liquid formulation for antibody drugs. Biochim Biophys Acta 2014;1844:2041–52.
   PubMed Web of Science ®Google Scholar
• Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 2006;58:707–22.
   PubMed Web of Science ®Google Scholar
• Ratanji KD, Derrick JP, Dearman RJ, et al. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 2014;11:99–109.
   PubMed Web of Science ®Google Scholar
• Connolly BD, Petry C, Yadav S, et al. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J 2012;103:69–78.
   PubMed Web of Science ®Google Scholar
• Pineda C, Castañeda Hernández G, Jacobs IA, et al. Assessing the immunogenicity of biopharmaceuticals. BioDrugs 2016;30:195–206.
   PubMed Web of Science ®Google Scholar
• van Beers MM, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 2012;7:1473–84.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, et al. Antibody structure, instability, and formulation. J Pharm Sci 2007;96:1–26.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Kumar S, Singh SK, et al. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. MAbs 2016;8:216–28.
   PubMed Web of Science ®Google Scholar
• Zheng JY, Janis LJ. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm 2006;308:46–51.
   PubMed Web of Science ®Google Scholar
• Usami A, Ohtsu A, Takahama S, et al. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 1996;14:1133–40.
   PubMed Web of Science ®Google Scholar
• Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta 2014;1844:1943–50.
   PubMed Web of Science ®Google Scholar
• Cicerone MT, Pikal MJ, Qian KK. Stabilization of proteins in solid form. Adv Drug Deliv Rev 2015;93:14–24.
   PubMed Web of Science ®Google Scholar
• Chang BS, Hershenson S. Practical approaches to protein formulation development. Pharm Biotechnol 2002;13:1–25.
   PubMedGoogle Scholar
• Crowe JH, Carpenter JF, Crowe LM. The role of vitrification in anhydrobiosis. Annu Rev Physiol 1998;60:73–103.
   PubMed Web of Science ®Google Scholar
• Andya JD, Hsu CC, Shire SJ. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharm Sci 2003;5:E10.
   PubMedGoogle Scholar
• Barnard JG, Singh S, Randolph TW, et al. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 2011;100:492–503.
   PubMed Web of Science ®Google Scholar
• Garidel P, Pevestorf B, Bahrenburg S. Stability of buffer-free freeze-dried formulations: a feasibility study of a monoclonal antibody at high protein concentrations. Eur J Pharm Biopharm 2015;97:125–39.
   PubMed Web of Science ®Google Scholar
• Duddu SP, Dal Monte PR. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res 1997;14:591–5.
   PubMed Web of Science ®Google Scholar
• Duddu SP, Zhang G, Dal Monte PR. The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody. Pharm Res 1997;14:596–600.
   PubMed Web of Science ®Google Scholar
• Chang LL, Shepherd D, Sun J, et al. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J Pharm Sci 2005;94:1445–55.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Mensink MA, de Jager A, et al. Size and molecular flexibility of sugars determine the storage stability of freeze-dried proteins. Mol Pharm 2015;12:684–94.
   PubMed Web of Science ®Google Scholar
• Wang B, Tchessalov S, Warne NW, et al. Impact of sucrose level on storage stability of proteins in freeze-dried solids: I. correlation of protein-sugar interaction with native structure preservation. J Pharm Sci 2009;98:3131–44.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Lam X, Kendrick B, et al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 2001;90:310–21.
   PubMed Web of Science ®Google Scholar
• Khan TA, Mahler HC, Kishore RS. Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm 2015;97:60–7.
   PubMed Web of Science ®Google Scholar
• Hillgren A, Lindgren J, Alden M. Protection mechanism of tween 80 during freeze-thawing of a model protein, LDH. Int J Pharm 2002;237:57–69.
   PubMed Web of Science ®Google Scholar
• Imamura K, Murai K, Korehisa T, et al. Characteristics of sugar surfactants in stabilizing proteins during freeze-thawing and freeze-drying. J Pharm Sci 2014;103:1628–37.
   PubMed Web of Science ®Google Scholar
• Liu L, Qi W, Schwartz DK, et al. The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study. J Pharm Sci 2013;102:2460–70.
   PubMed Web of Science ®Google Scholar
• Carpenter JF, Chang BS, Garzon-Rodriguez W, et al. Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol 2002;13:109–33.
   PubMedGoogle Scholar
• Jayasundera M, Adhikari B, Adhikari R, et al. The effects of proteins and low molecular weight surfactants on spray drying of model sugar-rich foods: powder production and characterisation. J Food Eng 2011;104:259–71.
   Web of Science ®Google Scholar
• Lee SH, Heng D, Ng WK, et al. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm 2011;403:192–200.
   PubMed Web of Science ®Google Scholar
• Gerhardt A, Bonam K, Bee JS, et al. Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces. J Pharm Sci 2013;102:429–40.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang YJ, Wang DQ. Dual effects of Tween 80 on protein stability. Int J Pharm 2008;347:31–8.
   PubMed Web of Science ®Google Scholar
• Hawe A, Kasper JC, Friess W, et al. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 2009;38:79–87.
   PubMed Web of Science ®Google Scholar
• Mahler H, Senner F, Maeder K, et al. Surface activity of a monoclonal antibody. J Pharm Sci 2009;98:4525–33.
   PubMed Web of Science ®Google Scholar
• Wiesbauer J, Prassl R, Nidetzky B. Renewal of the air-water interface as a critical system parameter of protein stability: aggregation of the human growth hormone and its prevention by surface-active compounds. Langmuir 2013;29:15240–50.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013;14:962–70.
   PubMed Web of Science ®Google Scholar
• Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427–40.
   PubMed Web of Science ®Google Scholar
• Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 2014;6:553–67.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab vs placebo in combination with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:1653–61.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:344–54.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69–74.
   PubMed Web of Science ®Google Scholar
• Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012;13:869–78.
   PubMed Web of Science ®Google Scholar
• Jezek J, Rides M, Derham B, et al. Viscosity of concentrated therapeutic protein compositions. Adv Drug Deliv Rev 2011;63:1107–17.
   PubMed Web of Science ®Google Scholar
• Narasimhan C, Mach H, Shameem M. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. Ther Deliv 2012;3:889–900.
   PubMedGoogle Scholar
• Kamerzell TJ, Kanai S, Liu J, et al. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J Phys Chem B 2009;113:6109–18.
   PubMed Web of Science ®Google Scholar
• Some D, Pollastrini J, Cao S. Characterizing reversible protein association at moderately high concentration via composition-gradient static light scattering. J Pharm Sci 2016;105:2310–18.
   PubMed Web of Science ®Google Scholar
• Liu J, Nguyen MD, Andya JD, et al. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 2005;94:1928–40.
   PubMed Web of Science ®Google Scholar
• Yadav S, Sreedhara A, Kanai S, et al. Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res 2011;28:1750–64.
   PubMed Web of Science ®Google Scholar
• Bauer KC, Suhm S, Wöll AK, et al. Impact of additives on the formation of protein aggregates and viscosity in concentrated protein solutions. Int J Pharm 2016;516:82–90.
   PubMed Web of Science ®Google Scholar
• Inoue N, Takai E, Arakawa T, et al. Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection. J Biosci Bioeng 2014;117:539–43.
   PubMed Web of Science ®Google Scholar
• Srinivasan C, Weight AK, Bussemer T, et al. Non-aqueous suspensions of antibodies are much less viscous than equally concentrated aqueous solutions. Pharm Res 2013;30:1749–57.
   PubMed Web of Science ®Google Scholar
• Bowen M, Armstrong N, Maa Y. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J Pharm Sci 2012;101:4433–43.
   PubMed Web of Science ®Google Scholar
• Morales JO, McConville JT. Novel strategies for the buccal delivery of macromolecules. Drug Dev Ind Pharm 2014;40:579–90.
   PubMed Web of Science ®Google Scholar
• Leleux J, Williams RO, III. Recent advancements in mechanical reduction methods: particulate systems. Drug Dev Ind Pharm 2014;40:289–300.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505–22.
   PubMed Web of Science ®Google Scholar
• Chen M, Ouyang H, Zhou S, et al. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Cell Immunol 2014;287:91–9.
   PubMed Web of Science ®Google Scholar
• Son S, Lee WR, Joung YK, et al. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm 2009;368:178–85.
   PubMed Web of Science ®Google Scholar
• Joung YK, Son S, Jang JY, et al. Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody. Pharm Res 2012;29:932–42.
   PubMed Web of Science ®Google Scholar
• Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 2013;50:341–52.
   PubMed Web of Science ®Google Scholar
• Srinivasan AR, Shoyele SA. Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance. AAPS Pharm Sci Tech 2013;14:200–10.
   PubMed Web of Science ®Google Scholar
• Srinivasan AR, Lakshmikuttyamma A, Shoyele SA. Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells. Mol Pharm 2013;10:3275–84.
   PubMed Web of Science ®Google Scholar
• Erdemli Ö, Usanmaz A, Keskin D, et al. Characteristics and release profiles of MPEG-PCL-MPEG microspheres containing immunoglobulin G. Colloids Surf B Biointerfaces 2014;117:487–96.
   PubMed Web of Science ®Google Scholar
• Marquette S, Peerboom C, Yates A, et al. Encapsulation of immunoglobulin G by solid-in-oil-in-water: Effect of process parameters on microsphere properties. Eur J Pharm Biopharm 2014;86:393–403.
   PubMed Web of Science ®Google Scholar
• Marquette S, Peerboom C, Yates A, et al. Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres. Int J Pharm 2014;470:41–50.
   PubMed Web of Science ®Google Scholar
• Moshaverinia A, Ansari S, Chen C, et al. Co-encapsulation of anti-BMP2 monoclonal antibody and mesenchymal stem cells in alginate microspheres for bone tissue engineering. Biomaterials 2013;34:6572–9.
   PubMed Web of Science ®Google Scholar
• Li X, Ye X, Qi J, et al. EGF and curcumin co-encapsulated nanoparticle/hydrogel system as potent skin regeneration agent. Int J Nanomedicine 2016;11:3993–4009.
   PubMed Web of Science ®Google Scholar
• Tashakori-Sabzevar F, Mohajeri SA. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses. Drug Dev Ind Pharm 2015;41:703–13.
   PubMed Web of Science ®Google Scholar
• Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem Rev 2012;112:2853–88.
   PubMed Web of Science ®Google Scholar
• Xu X, Weng Y, Xu L, et al. Sustained release of avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol 2013;60:272–6.
   PubMed Web of Science ®Google Scholar
• Wang C, Hwang Y, Chiang P, et al. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 2012;13:40–8.
   PubMed Web of Science ®Google Scholar
• Rauck BM, Friberg TR, Medina MC, et al. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci 2014;55:469–76.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Barros M, Stansbury JW, et al. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm 2013;10:2858–67.
   PubMed Web of Science ®Google Scholar
• Lee ALZ, Ng VWL, Gao S, et al. Injectable hydrogels from triblock copolymers of vitamin E-functionalized polycarbonate and poly (ethylene glycol) for subcutaneous delivery of antibodies for cancer therapy. Adv Funct Mater 2014;24:1538–50.
   Web of Science ®Google Scholar
• Andrew JS, Anglin EJ, Wu EC, et al. Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide. Adv Funct Mater 2010;20:4168–74.
   PubMed Web of Science ®Google Scholar
• Schweizer D, Schönhammer K, Jahn M, et al. Protein-polyanion interactions for the controlled release of monoclonal antibodies. Biomacromolecules 2013;14:75–83.
   PubMed Web of Science ®Google Scholar
• Schweizer D, Vostiar I, Heier A, et al. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation. J Control Release 2013;172:975–82.
   PubMed Web of Science ®Google Scholar
• Parakh S, Parslow AC, Gan HK, et al. Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opin Drug Deliv 2016;13:401–19.
   PubMed Web of Science ®Google Scholar